Lipiflow Treatment Prior to Cataract Surgery found to be Saf
A Study was conducted to investigate the effects of preoperative Lipiflow treatment prior to cataract surgery on meibomian gland dysfunction (MGD) and dry eye induced by surgery.

This research included 124 eyes from 124 patients who were scheduled for senile cataract surgery. Based on the administration of Lipiflow medication three weeks prior to cataract surgery, participants were randomly assigned to control or Lipiflow classes. At the baseline visit and 1 and 3 months postoperatively, MG atrophy, degree of gland expressibility, and consistency of gland secretions were evaluated for meibomian gland (MG) evaluation.

Ocular surface parameters of tear film break-up time (TBUT), Oxford corneal staining score, and tear film lipid layer thickness (LLT) were measured at each visit. Ocular Surface Disease Index (OSDI) and Dry Eye Questionnaire (DEQ) were also assessed.

--The control group exhibited a significant decrease in MG expressibility, worsened meibum quality, decreased LLT, and worsened corneal staining following cataract surgery. Also, dry eye symptom showed significant worsening.

--Conversely, the Lipiflow group showed significantly improved MG patency and meibum quality, increased TBUT, and reduced corneal staining, and presented improved subjective outcomes reported on both OSDI and DEQ.

--The improvement of each parameter in the Lipiflow group showed a linear correlation with baseline MGD grade.

--In addition, patients without baseline MGD showed less worsening or improvement of MGD and dry eye induced by surgery, with preoperative Lipiflow treatment.

To summarize, preoperative Lipiflow care before cataract surgery can be a safe and convenient way to relieve MGD and dry eye caused by surgery. To prevent the production of MGD and dry eye caused by ocular surgeries, it may be recommended not only for patients with preoperative MGD, but also for those who do not have baseline MGD.